Americans preparing to enroll in 2026 Affordable Care Act (ACA) health insurance plans are facing steep premium hikes, with monthly costs expected to more than double on average. The sharp rise stems from the expiration of COVID-19 pandemic-era subsidies that have been central to the ongoing U.S. government shutdown. These subsidies, which boosted enrollment to a record 24 million since 2021, are set to expire at the end of the year, potentially increasing the number of uninsured Americans and influencing election outcomes.
According to health research firm KFF, ACA enrollees will see average premiums rise by 114%. While 22 million people currently receive subsidies, the impact will vary widely. For example, 24-year-old Californian Austin Jeha’s monthly premium is expected to jump from $215 to $436. Like many, he relies on his ACA plan for essential medical care and is urging Congress to extend the subsidies.
The budget impasse in Washington has left much of the government shuttered since October 1. Democrats are pushing to include ACA funding in any reopening deal, while Republicans insist on restoring government funding first. Residents of Republican-led states such as Florida, Texas, and Georgia are expected to be hit hardest, as limited Medicaid coverage forces many low-income workers to depend on ACA plans.
If subsidies expire, households earning just above 400% of the federal poverty line—around $84,600 for a couple—could see their premiums quadruple. Experts warn enrollment will decline even if subsidies are later reinstated, as consumers may abandon plans after seeing higher rates. The Congressional Budget Office estimates over 4 million Americans could lose coverage without renewed tax credits. Rising healthcare costs and insurer exits, such as CVS Health’s Aetna leaving the ACA market, have already driven a 26% increase in premiums. For many families, healthcare remains essential but increasingly unaffordable.


Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Bachelet Pushes Forward With UN Secretary-General Bid Despite Chile's Withdrawal
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Denmark Election 2025: Social Democrats Suffer Historic Losses Amid Migration and Cost-of-Living Tensions
Pentagon Revises Media Access Policy Following Court Order
TSA Absences Surge During Government Shutdown as ICE Agents Prepare Airport Deployment
SEC Eyes Shift to Semiannual Corporate Reporting, Ending 50-Year Quarterly Mandate
China Escalates BHP Iron Ore Ban Amid Contract Dispute
FCC Chairman Threatens Broadcasters Over "Fake News" Amid Iran War Coverage Debate
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation
Oil Prices Rebound as Iran Denies U.S. Talks, Middle East Tensions Persist
Gold Prices Fall for Tenth Straight Session Amid Iran Uncertainty and Rate Concerns
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 



